TNFRSF8 and Hodgkins lymphoma: CD30 is an excellent immunotherapy target due to its expression on multiple pediatric and adult malignancies, including Hodgkin lymphoma (HL), peripheral T cell lymphoma, cutaneous T cell lymphoma, acute myeloid leukemia, testicular germ cell tumors, and numerous other cancers (1–5).